Novartis Pharma Obtains Additional Approval for Osteoclastic Inhibitor Zometa.
Tokyo, Japan, Apr 21, 2006 - (JCN) - Novartis Pharma announced on April 20 that it had obtained additional approval for Zometa Injection 4mg, its proprietary osteoclastic inhibitor, from the Ministry of Health, Labor and Welfare.
The agent is currently available for the treatment of bone metastasis in multiple myeloma (MM) and solid tumor. Zometa, a bisphosphonate bisphosphonate /bis·phos·pho·nate/ (bis-fos´fo-nat) diphosphonate. agent, is currently available in over 90 countries worldwide.
This is the first agent for bone lesion in MM and solid tumor that has been approved in Japan. Novartis Phama plans to co-promote the agent with Nippon Kayaku.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion